SCHEMBL3964096

SCHEMBL3964096

O=C(NC1CC1)c1cccc2sc(-c3nc(Cl)ncc3Cl)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.44
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
HPGD P15428 4/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
DYRK1A Q13627 2/20 0.39
DYRK1B Q9Y463 2/20 0.39
DRD4 P21917 3/20 0.38
PIM1 P11309 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
KMT2A Q03164 2/20 0.38
GAA P10253 1/20 0.38
MEN1 O00255 1/20 0.38
DGAT1 O75907 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3961444 0.90 L3MBTL1 (0.48) P2RX7RAB9ANPC1L3MBTL1HPGD
SCHEMBL3965483 0.90 RAB9A (0.42) P2RX7RAB9ANPC1L3MBTL1HPGD
SCHEMBL3965319 0.90 RAB9A (0.42) P2RX7RAB9ANPC1L3MBTL1HPGD
SCHEMBL3966800 0.85 JAK2 (0.41) RAB9ANPC1HPGDKDM4EALDH1A1
Hydrochloric Acid SCHEMBL3963698 0.84 AXL (0.38) P2RX7RAB9ANPC1L3MBTL1DRD4
SCHEMBL3961953 0.84 CCNT1 (0.39) P2RX7RAB9ANPC1L3MBTL1CHEK1
SCHEMBL3961942 0.84 P2RX7 (0.38) P2RX7RAB9ANPC1L3MBTL1HPGD
SCHEMBL3961637 0.82 BTK (0.39) KDM4EALDH1A1KMT2AGAAMEN1
SCHEMBL3969565 0.82 BTK (0.38) RAB9ANPC1KDM4EALDH1A1KMT2A
SCHEMBL3961504 0.81 TYRO3 (0.40) P2RX7RAB9ANPC1CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG P2RX7 1253/4885RAB9A 3349/4885NPC1 2292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.